BRTX BioRestorative Therapies, Inc.

CIK 0001505497 22 ready 8-Ks latest May 29, 2026, 5:07 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 22

Latest filing May 29, 2026, 5:07 PM ET

Top materiality 0.78

Event mix other_material ×14 · earnings ×4 · other ×3

Sentiment 2 pos · 2 neg · 18 neu

Latest earnings reported 2025-Q3

Recent 8-K filings for BRTX

Highest-materiality recent filing

BioRestorative presents Phase 2 data for BRTX-100: >50% improvement in pain/function in >70% of subjects

June 13, 2025, 7:59 PM ET other material materiality 0.78 positive item 7.01 item 9.01

Preliminary blinded data from 36 subjects in Phase 2 trial of BRTX-100 for chronic lumbar disc disease presented at ISSCR 2025.
Over 74% of subjects showed >50% improvement in function (ODI) by week 52; over 72% had >50% pain reduction (VAS).

Read filing →

May 29, 2026, 5:07 PM ET other material materiality 0.70 neutral item 5.02 item 5.07 item 9.01 ◈ Shareholder Votes

BRTX shareholders approve 20x increase in authorized shares; CEO/CFO sign 3-year employment agreements

CEO Lance Alstodt signed 3-year employment agreement with $600k annual salary, unchanged.
May 1, 2026, 7:59 PM ET other material materiality 0.50 neutral item 5.02

BioRestorative Therapies approves 2025 executive bonuses; CEO bonus $300K, VP $287.5K, CFO $140K

CEO Lance Alstodt awarded $300K cash bonus and $1.5M in option awards; total 2025 compensation $2.4M.
April 23, 2026, 7:59 PM ET other material materiality 0.20 neutral item 7.01 item 9.01

BioRestorative Therapies posts updated corporate presentation; no financial details disclosed

Updated presentation made available on company website on April 23, 2026.
February 17, 2026, 6:59 PM ET other material materiality 0.55 neutral item 1.01 item 7.01 item 9.01 ◈ Material Agreements

BioRestorative raises $5.0M in public offering of stock and warrants to fund clinical programs

Offering of 14.3M shares (or pre-funded warrants) and 14.3M five-year warrants at $0.35/unit closed Feb 13.
November 12, 2025, 6:59 PM ET earnings materiality 0.50 neutral item 2.02 item 7.01 item 9.01

BioRestorative Therapies reports Q3 2025 results; press release content omitted from filing

Press release dated November 12, 2025, announced Q3 2025 financial results and business update.
October 8, 2025, 7:59 PM ET other material materiality 0.45 neutral item 1.01 item 3.02 item 7.01 item 9.01

BioRestorative Therapies raises $1.085M in registered direct offering at $1.60/share; warrants at $2.75

Registered direct offering of 678,125 shares at $1.60/share, gross proceeds $1.085M; closing expected Oct 8, 2025.
September 25, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

BioRestorative Therapies shareholders elect directors, approve stock plan amendment, ratify auditor, okay exec pay

Elected Francisco Silva (1.59M for) and David Rosa (1.47M for) as Class II directors; ~3.33M broker non-votes.
August 14, 2025, 7:59 PM ET other materiality 0.20 neutral item 7.01 item 9.01

BioRestorative Therapies releases updated corporate presentation; no financial details in filing

Updated investor presentation posted on company website and furnished as Exhibit 99.1.
August 12, 2025, 7:59 PM ET earnings materiality 0.50 neutral item 2.02 item 7.01 item 9.01

BioRestorative Therapies issues Q2 2025 earnings; no figures in provided excerpt

Press release dated Aug 12, 2025 announces Q2 financial results and a business update.
June 13, 2025, 7:59 PM ET other material materiality 0.78 positive item 7.01 item 9.01

BioRestorative presents Phase 2 data for BRTX-100: >50% improvement in pain/function in >70% of subjects

Preliminary blinded data from 36 subjects in Phase 2 trial of BRTX-100 for chronic lumbar disc disease presented at ISSCR 2025.
May 14, 2025, 7:59 PM ET earnings materiality 0.30 neutral item 2.02 item 7.01 item 9.01

BioRestorative Therapies issues Q1 2025 results press release; financial details not available

Company announced Q1 2025 financial results and business update on May 14, 2025.
April 21, 2025, 7:59 PM ET other material materiality 0.60 neutral item 4.01 item 9.01

BioRestorative Therapies replaces auditor Marcum with CBIZ after Marcum attest business acquired

Marcum LLP resigned as auditor on April 16, 2025; FY2024 and FY2023 reports unqualified except FY2024 includes going-concern paragraph.
March 27, 2025, 7:59 PM ET other materiality 0.30 neutral item 2.02 item 7.01 item 9.01

BioRestorative Therapies to release FY2024 results after market close on March 27, 2025, with conference call

Financial results for year ended Dec 31, 2024 will be released after market close on March 27, 2025.
February 10, 2025, 6:59 PM ET other material materiality 0.20 neutral item 7.01 item 9.01

BioRestorative Therapies presents at ORS 2025; VP Silva discusses development programs

Francisco Silva, VP of R&D, presented at Orthopaedic Research Society 2025 Annual Meeting on Feb 8.
November 13, 2024, 6:59 PM ET other material materiality 0.75 positive item 2.02 item 7.01 item 9.01

BioRestorative Q3 operating loss narrows 26% YoY; BRTX-100 Phase 2 data shows improvement

Q3 2024 operating loss $2.3M vs $3.1M YoY (26% improvement); net loss $1.1M ($0.13/sh).
November 7, 2024, 6:59 PM ET other material materiality 0.55 neutral item 7.01 item 9.01

BioRestorative to present Phase 2 BRTX-100 data at spine symposium; Q3 results call Nov 13

Additional preliminary 26-52 week blinded data from Phase 2 trial of BRTX-100 for chronic lumbar disc disease to be presented on Nov 13, 2024.
November 6, 2024, 6:59 PM ET other material materiality 0.50 neutral item 1.01 item 1.02 item 9.01

BioRestorative enters into $3.6M ATM offering agreement with Rodman & Renshaw; terminates prior JonesTrading ATM

Entered ATM agreement with Rodman & Renshaw on Nov 6, 2024 for up to $3.6M of common stock.
September 23, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07

BioRestorative shareholders approve doubling of stock incentive plan shares to 6.85M

Class I director Nickolay Kukekov re-elected with 2,050,111 votes for, 135,114 withheld, 2,048,738 broker non-votes.
August 13, 2024, 7:59 PM ET earnings materiality 0.50 neutral item 2.02 item 7.01 item 9.01

BioRestorative Therapies issues Q2 2024 results press release; specific figures not provided

Press release announcing Q2 2024 financial results was issued on August 13, 2024.
August 6, 2024, 7:59 PM ET other materiality 0.15 neutral item 2.02 item 7.01 item 9.01

BioRestorative Therapies schedules Q2 2024 earnings release and call for Aug 13

Financial results for Q2 2024 will be released after market close on Tuesday, August 13, 2024.
May 24, 2024, 7:59 PM ET other material materiality 0.70 negative item 4.02

BioRestorative Therapies restates financials due to warrant classification error; no cash impact

Previously issued annual (FY2023) and quarterly (Q1'22–Q3'23) financial statements should no longer be relied upon.
May 24, 2024, 7:59 PM ET regulatory materiality 0.70 negative item 3.01

BioRestorative receives Nasdaq notice for late 10-Q filing; no immediate delisting

Nasdaq notified BioRestorative on May 22, 2024 of non-compliance with Listing Rule 5250(c)(1) due to delinquent Form 10-Q for Q1 2024.

Earnings & guidance

2025-Q3 EPS reported -$1.26 filing →

Materiality & sentiment trend

Max materiality 0.78 · Median 0.50 · Most common event other_material

2 positive 2 negative 18 neutral

source · BRTX on sec.gov